CandlesenseCandlesense
News/Companies/AMIX

AMIX News

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

AMIX

(NASDAQ:AMIX) Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”)

September 4, 2025Clinical Trials
Read more →

Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

AMIX

(NASDAQ:AMIX) THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

September 2, 2025Conference
Read more →

Autonomix Medical Secures Ethics Approval For Cancer Pain Clinical Trial in Uzbekistan; On Track To Commence Enrollment In June 2025

AMIX

June 5, 2025
Read more →

United States Patent And Trademark Office Grants Autonomix Medical U.S. Patent No. 12,257,071 ('071 Patent) Titled 'Controlled sympathectomy and micro-ablation systems and methods.'

AMIX

May 15, 2025
Read more →

Autonomix Medical Reiterates Plans For Follow-on Phase To PoC 2 Evaluating Safety And Effectiveness Of Delivering Transvascular Energy To Ablate Relevant Problematic Nerves And Mitigate Cancer Pain

AMIX

May 13, 2025
Read more →

Autonomix Medical Releases Testimonial From Patient Participating In Initial Phase Of Its First-in-human Proof-of-concept Trial Evaluating The Safety And Effectiveness Of Delivering Transvascular Energy To Ablate Relevant Nerves And Mitigate Pain In Patie

AMIX

May 5, 2025
Read more →

Autonomix Medical Reports Outcomes In Initial Phase Of First-in-Human Proof-of-Concept Trial In Pancreatic Cancer Pain And Initiates Market Expansion Study for Visceral Cancer Pain

AMIX

April 30, 2025
Read more →

Maxim Group Initiates Coverage On Autonomix Medical with Buy Rating, Announces Price Target of $5

AMIX

April 29, 2025
Read more →

12 Health Care Stocks Moving In Monday's After-Market Session

AMIX

April 28, 2025
Read more →

Autonomix Medical Secures European Patent For Its Catheter-Based Technology

AMIX

April 16, 2025
Read more →

Autonomix Medical Granted U.S. Patent Covering Sensing Data Collection And Processing With Company's Proprietary Catheter-Based Technology

AMIX

March 20, 2025
Read more →

Autonomix Medical Completes Integration And Design Enhancements Of Apex 6 Generator

AMIX

March 14, 2025
Read more →

Autonomix Medical Abstract Accepted For Poster Presentation At 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting Mar. 31

AMIX

March 6, 2025
Read more →

Autonomix Medical Q3 EPS $(1.46) Beats $(2.40) Estimate

AMIX

February 13, 2025
Read more →

Autonomix Medical Has Received A Notice Of Allowance For A U.S. Patent Titled Smart Torquer And Methods Of Using The Same (For Engaging Intravascular Devices, Such As Guide Wires Or Catheters, During Surgery)

AMIX

January 15, 2025
Read more →

12 Health Care Stocks Moving In Friday's Intraday Session

AMIX

November 1, 2024
Read more →

12 Health Care Stocks Moving In Thursday's Intraday Session

AMIX

October 31, 2024
Read more →

Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain with Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of Life Im

AMIX

October 31, 2024
Read more →

12 Health Care Stocks Moving In Thursday's Pre-Market Session

AMIX

October 31, 2024
Read more →

12 Health Care Stocks Moving In Thursday's Pre-Market Session

AMIX

October 31, 2024
Read more →